The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

AMRX FINANCIAL STATEMENTS

Amneal Pharmaceuticals, Inc. Class A Common Stock — balance sheet, income statement and cash flow trends

AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
01 B2 B3 B202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue3.1 B $Gross Profit1.2 B $ · 39%Operating Income246.6 M $ · 8%Pre-tax Income201.2 M $ · 6%Net Income to Owners157.6 M $ · 5%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue3.1 B $+9.3%
Gross Profit1.2 B $+14.1%
Operating Income246.6 M $-34.5%
EBITDA447.8 M $-23.3%
Net Income to Owners157.6 M $+4,569.7%

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
02 B4 B202120222023202420252026

Capital Structure

Q2 2026
Total Assets3.8 B
  • Equity33 M $1%
  • Current Liabilities883.2 M $24%
  • Long-term Liabilities2.8 B $75%

Key Figures

YoY change
Total Assets3.8 B $+10.3%
Total Liabilities3.7 B $+7.9%
Total Equity33 M $—
Cash & ST Investments127.6 M $+57.2%
Total Debt2.8 B $+8.1%
Net Debt2.7 B $+6.5%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
0200 M400 M202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
0100 M200 M220 M $Operating-89.6 M $Investing-7.8 M $Financing122.7 M $Net Change

Key Figures

YoY change
Operating Cash Flow220 M $-37.3%
Capital Expenditures72.1 M $-18.6%
Free Cash Flow148 M $-43.6%
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on AMRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 2, 26. This content is for informational purposes only and is not investment advice.